Biohaven Ltd.
BHVN
Biohaven is a biopharmaceutical company focused on the discovery, development, and commercialization of life-changing treatments in key therapeutic areas, including immunology, neuroscience, and oncology. We are advancing our innovative portfolio of therapeutics, leveraging our proven drug development experience and multiple proprietary drug development platforms.
Valuation & Multiples
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue
N/A
Net Income (TTM)
-$543M
▲ +12.7% YoY
Op. Margin
–
ROIC
-463.63%
▼ -58.9pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
-$473M
▼ -4.0% YoY
Op. Cash Flow (TTM)
-$473M
▼ -4.6% YoY
Net Debt
-$125M
Net Cash Position
Cash & Equiv.
$161M
Continue Research
Peers
Pharmaceutical Preparations · Pick stocks to compare with BHVN
Held by ETFs
BHVN is in 37 US ETFs. The largest of them, with BHVN's weight in each:
Biohaven (BHVN) in two numbers
Questions about Biohaven
Does Biohaven (BHVN) pay a dividend?
No. Biohaven (BHVN) does not pay a dividend, and no dividend payment appears anywhere in the filing history we hold. Nor has its share count fallen meaningfully over the last twelve months, so cash is kept in the business. The Dividends tab shows its cash returns.
Source: 10-Q filed 26 Oct 2026 (period ending 30 Sept 2026), SEC. Price: last close 20 Nov 2026. How this is calculated. Sector medians are approximate S&P 500 benchmarks and update periodically. Analysis, not investment advice.
Spot a number that looks wrong? Check it in BHVN's SEC filings or
Download this analysis as a PDF (Pro)
Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Keep analysing BHVN
A free account gives you 10 stocks a day, a watchlist and price alerts.
Already have an account?
Or come back tomorrow. Stocks on your watchlist are always free to view.